Wednesday, 15 Aug 2018

You are here

Predicting Autoimmune Progression in ANA+ Patients

Positive tests results for antinuclear antibodies (ANAs) are frequently referred to rheumatology despite their poor predictive value, even in individuals who are ‘At Risk’ for autoimmune connective tissue diseases (AI-CTDs). A new study shows that combining ANA positive with interferon-stimulated gene expression increased the liklihood of progression to AI-CTD.

This prospective observational study studied 118 individuals who were ANA positive, had one or more SLE criteria for <12 months and were treatment-naïve. They also used 49 healthy controls (HCs) and 114 SLE were used as negative and positive controls. 

Over a 12-month period, 19/118 (16%) progressed to AI-CTD (SLE=14, primary Sjogren’s=5).

Baseline IFN (IFN-A, IFN-B) scores differed among At-Risk, HCs and SLE groups (p<0.001) and were elevated in At-Risk who progressed to AI-CTD at 12 months.

Those who progressed to AI-CTD did not have other distinguishing baseline clinical characteristics or ultrasound findings.

The odds of progression were more likely in those with a family history of autoimmune rheumatic disease  (OR 8.2 (95% CI 1.58 to 42.53) and IFN-Score-B (OR 3.79;1.50–9.58).

While gene testing for IFN signatures would be interesting, if not advantageous, the question remains whether this would be cost effective and predictive in individuals without a positive family history and without lupus-specific clinical characteristics.  Nonethless, this approach allows for the potential of early stratification of individuals At-Risk for AI-CTD.

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Ethnicity Matters in Sjogren's Syndrome

Among the ethnically diverse residents of Manhattan, certain groups had markedly different incidence rates of primary Sjogren's syndrome, a retrospective study found.

Women were more often affected, with age-adjusted incidence rates being highest for Asian women, at 10.5 (95% CI 6.6-15.7) per 100,000 person-years, according to Peter M. Izmirly, MD, of New York University School of Medicine in New York City, and colleagues.

Statin Associated with an Increase in Inflammatory Myopathy

JAMA Internal Medicine reports that exposure to statin medications may be linked to histologically confirmed idiopathic inflammatory myositis.

A population-based, case-control study, using the South Australian Myositis Database, examined 221 patients with idiopathic inflammatory myositis (IIM) matched 1:3 with 662 controls. The 221 IIM cases had a mean age of 62.2 years, and 132 (59.7%) were female

Type I Interferon Drives Photosensitivity in Cutaneous Lupus

Kahlenberg and coworkers have reported in ARD that interferon kappa (IFN-κ) is a key regulator of type I interferon (IFN) photosensitive responses in patients with cutaneous lupus erythematosus (CLE).

Latin American Clinical Practice Guidelines for Lupus

The Annals of Rheumatic Disease have published the recently developed Latin American clinical practice guidelines for systemic lupus erythematosus (SLE) addressing the best pharmacologic interventions for musculoskeletal, mucocutaneous, kidney, cardiac, pulmonary, neuropsychiatric, hematological manifestations and the antiphospholipid syndrome.

Baricitinib Effective in SLE Trial

Dan Wallace and colleagues report in Lancet the results of a phase II study of the selective baricitinib, an oral selective Janus kinase (JAK1 and JAK2) inhibitor, in patients with systemic lupus erythematosus, demonstrating the efficacy and safety of JAK1/2 inhibition with baricitinib as a new potential oral therapy for SLE.